Embedded Files
Developing novel treatments for MLL-rearranged Leukemias
Developing novel treatments for MLL-rearranged Leukemias
AML can be caused by a number of different mutations in the hematopoietic cell. One common mutation found in AML is a chromosome rearrangement involving the mixed-lineage leukemia (MLL) gene. These MLL-rearranged leukemias are associated with poor prognosis and limited therapeutic options. Our lab looks at gene expression changes that occur as a result of these gene rearrangement in an effort to identify critical pathways in MLL-r leukemias that could be inhibited in order to curb cancer growth.
Meyer, C. et al (2006). The MLL recombinome of acute leukemias. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 20. 777-84. 10.1038/sj.leu.2404150.
Understanding metabolic vulnerabilities in AML
Understanding metabolic vulnerabilities in AML
AML cells rely heavily on glutamine for their survival. Novel therapies such as Telaglenastat (CB-839) that inhibit the breakdown of glutamine into glutamate have shown promise in clinical trials. We are interested in looking at prosurvival pathways that are upregulated in response to the inhibition of glutamine metabolism in AML cells to identify potential resistance mechanisms. By identifying and inhibiting these prosurvival pathways we aim to increase the efficacy of glutaminase inhibitors.
Page updated
Google Sites
Report abuse